New Cancer Treatment Can Eliminate Tumors

Scientists are reporting a potentially groundbreaking development in the fight against pancreatic cancer after clinical trials revealed that a new drug combined with chemotherapy could dramatically shrink tumors, with some patients showing no detectable signs of cancer following treatment.

The findings are generating considerable excitement among medical researchers because pancreatic cancer remains one of the deadliest and most difficult forms of the disease to treat.

The treatment involves daraxonrasib, a once-daily oral medication sold under the name Rasonque, which received approval in August 2026.

Researchers have now discovered that combining the medication with traditional chemotherapy may produce substantially stronger results than previously anticipated.

Oncologist Dr. Wungki Park, who presented the latest findings, described the development in remarkable terms.

“This is the closest to cure,” Park declared. “We’ve never seen such a thing.”

The clinical trial examined patients with Stage 4 pancreatic cancer, an advanced form of the disease that has spread to other parts of the body.

Participants received daraxonrasib alongside two chemotherapy medications, gemcitabine and nab-paclitaxel.

The results revealed significant improvements in controlling the disease.

Approximately nine out of ten patients experienced tumors that either shrank or remained stable during treatment.

Even more encouraging, roughly three out of five participants experienced substantial tumor shrinkage or disappearance.

Researchers reported that 8.2% of patients, approximately one in twelve, had no detectable cancer at the end of the study.

More than 76% of participants survived beyond one year while receiving treatment.

For patients diagnosed with advanced pancreatic cancer, those findings represent a potentially significant advancement.

We don’t spam! Read our privacy policy for more info.

Park described the results as a “massive, massive breakthrough” in the fight against the disease.

The findings are especially notable because of the length of time researchers followed the patients.

The clinical trial had a median follow-up period of 18.3 months, allowing scientists to better evaluate whether improvements persisted beyond the initial treatment period.

Researchers also reported median progression-free survival exceeding one year, suggesting that many patients experienced extended periods without their cancer worsening.

The findings provide a promising foundation for examining whether the combination could become a first-line treatment option for pancreatic cancer.

However, having no detectable cancer does not necessarily mean a patient has been permanently cured, and additional research is needed to establish the treatment’s long-term effectiveness.

Daraxonrasib had already generated considerable interest before the latest combination trial.

Previous research found that the drug alone increased median survival from approximately 6.7 months to 13.2 months.

The medication works by targeting KRAS, a mutated protein that can drive uncontrolled cancer cell growth.

Dr. Nicholas Hornstein, a medical oncologist at Northwell’s Lenox Hill Hospital, compared the malfunctioning protein to a stuck accelerator that continuously instructs cancer cells to multiply.

By interfering with that process, daraxonrasib aims to slow or interrupt tumor growth.

The treatment offers hope against a disease that has historically resisted chemotherapy, radiation, immunotherapy and other targeted medications.

Pancreatic cancer has an overall five-year survival rate of approximately 13.7 percent, making it the third-deadliest cancer.

The disease has claimed the lives of prominent figures including Alex Trebek, Patrick Swayze, Alan Rickman and Jerry Springer.

Nevertheless, the new medication is not without serious drawbacks.

Former Republican Sen. Ben Sasse, who was diagnosed with Stage 4 pancreatic cancer in December 2025, previously discussed his experience receiving daraxonrasib, per the New York Post.

Sasse revealed that the medication caused severe skin-related complications.

“I take it orally, but it’s a nasty drug,” he explained in April.

Clinical trial data indicated that dermatologic toxicity occurred in approximately 86 percent of patients taking the medication, with 10 percent experiencing severe reactions.

Although Sasse survived significantly longer than his initial prognosis of three to four months, he revealed in September that some of his tumors were developing resistance to treatment.

His experience illustrates both the potential benefits and considerable challenges associated with the medication.

Researchers are now focusing on whether combining daraxonrasib with chemotherapy can produce stronger and longer-lasting results for patients with advanced disease.

Dr. Alan Sandler, chief development officer of Revolution Medicines, emphasized the urgency of developing better options for individuals facing metastatic pancreatic cancer.

He explained that existing chemotherapy regimens offer limited benefits for many patients, making new treatment approaches essential.

While the latest findings do not establish a permanent cure, the ability to make previously detectable tumors disappear in some patients has generated new optimism.

For individuals confronting one of medicine’s most formidable cancers, the research offers a potentially important step toward treatments capable of extending survival and achieving deeper responses than previously possible.

By Reece Walker

Reece Walker covers news and politics with a focus on exposing public and private policies proposed by governments, unelected globalists, bureaucrats, Big Tech companies, defense departments, and intelligence agencies.

Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
0
Would love your thoughts, please comment.x
()
x